Trial Profile
Compassionate Use of Vorinostat (MK0683) for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Sep 2022
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 07 Jan 2021 This trial has been completed in Ireland, according to European Clinical Trials Database record.
- 03 Mar 2012 Planned number of patients changed from 65 to 100 as reported by European Clinical Trials Database.
- 21 Feb 2012 Planned end date changed from 1 May 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.